Application No.: 10/518,405

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A tetrahydroquinoline derivative represented by the following formula (I) or pharmacologically acceptable salts thereof:

wherein R¹ represents a nitro group or a cyano group;

X represents CH-or O, provided that when X is CH, the dashed line represents a double bond;

m represents 0-or-1;

Y represents an alkylene group having 1 – 5 carbon atoms which may be substituted by a substituent selected from the group consisting of an alkyl group having 1 – 5 carbon atoms and a eveloalkyl group having 3 – 7 carbon atoms -C(CH₃)₂-CH₂-;

R² represents a hydrogen atom, an alkyl group having 1 – 5 carbon atoms, a cycloalkyl group having 3 – 7 carbon atoms or an aralkyl group having 7 – 9 carbon atoms;

Z represents B-O-Q

[wherein B represents an alkylene group having 1 - 5 carbon atoms which may be substituted by a substituent selected from the group consisting of an alkyl group having 1 - 5

Attorney Docket No.: Q85416

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/518,405

earbon atoms and a cycloalkyl group having 3 – 7 carbon atoms; Q is a hydrogen atom, an alkyl group having 1 – 5 carbon atoms or a cycloalkyl group having 3 – 7 carbon atoms which may be substituted by a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group and an alkoxy group having 1 – 5 carbon atoms, or an aryl group, a heteroaryl group or an aralkyl group having 7 – 9 carbon atoms which may have a substituent R³,

Z represents a heteroaryl group which may be substituted by 1 - 3 independent R^{11} 's, wherein the R^{11} 's independently have the same meaning as R^3 ;

R³ represents an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a halogen atom, an aryl group, a heteroaryl group, a nitro group, a cyano group, - A-R⁴ {wherein A represents -CO-, -CO₂-, -COS-, -CONR⁵-, -O-, -OCO-, -OSO₂-, -S-, SCO-, -SO₂-, -NR⁵-, -NR⁵CO-, -NR⁵SO₂-, -NR⁵CONH-, NR⁵CSNH- or -NR⁵COO- (wherein R⁵ represents a hydrogen atom, an alkyl group having 1 - 5 carbon atoms, a cycloalkyl group having 3 - 7 carbon atoms or an aralkyl group having 7 - 9 carbon atoms),

R⁴ is a hydrogen atom, an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a cycloalkyl group having 3 - 7 carbon atoms, a halogen atom, or an aryl group or a heteroaryl group which may be substituted by R⁶ (wherein R⁶ represents an alkyl group having 1 - 5 carbon atoms, an alkoxy group having 1 - 5 carbon atoms or a halogen atom), provided that when A is NR⁵- or -CONR⁵-, R⁴ and R⁵ may, together with the nitrogen atom to which they are bonded, form pyrrolidine or piperidine)}, or -A'-(CH₂)_n-R^{4'} {wherein A' represents a single bond, -CO-, -CO₂-, -COS-, -CONR^{5'}-, -O-, -OCO-, -OSO₂-, -S-, SCO-, -SO-, -SO₂-, -NR^{5'}-, -NR^{5'}CO-, -NR^{5'}SO₂-, -NR^{5'}CONH-, NR^{5'}CSNH- or -NR^{5'}COO- (wherein R^{5'} represents a hydrogen atom, an alkyl group having 1 - 5 carbon atoms, a cycloalkyl group having 3 - 7 carbon atoms or an aralkyl group having 7 - 9 carbon atoms), n represents an integer of 1 or

Attorney Docket No.: Q85416

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/518,405

2, R⁴ represents a hydrogen atom, an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a cycloalkyl group having 3 - 7 carbon atoms, a halogen atom, a hydroxyl group, a cyano group, an alkoxy group having 1 - 5 carbon atoms, an alkylacyloxy group having 2 - 5 carbon atoms, an alkoxycarbonyl group having 2 - 5 carbon atoms, an aryl group or a heteroaryl group which may be substituted by R⁶ (wherein R⁶ represents an alkyl group having 1 - 5 carbon atoms, an alkoxy group having 1 - 5 carbon atoms or a halogen atom), or -NR⁷ R⁸ (wherein R⁷ and R⁸ each independently have the same meaning as the aforementioned R⁵, provided that R⁷ and R⁸ may, together with the nitrogen atom to which they are bonded, form pyrrolidine or piperidine), provided that when A' is -NR⁵ or -CONR⁵, R⁴ and R⁵ may, together with the -N-(CH₂)_n- to which they are bonded, form pyrrolidine or piperidine}], or alternatively Z represents (CH₂)_r-W

[wherein r represents an integer of 0 - 2, W represents

a phenyl group having substituent R^9 at p-position, a naphthyl group which may have substituent R^{10} or a heteroaryl group which may be substituted by 1-3 independent R^{11} 's (wherein R^9 , R^{10} and R^{11} independently have the same meaning as the aforementioned R^3)].

2. (canceled).

3. (currently amended): The tetrahydroquinoline derivative according to claim 1, where Y is -CH(CH₃) CH₂- or -C(CH₃)₂-CH₂-, m is 0, R² is a hydrogen atom and Z is -W [wherein W is a heteroaryl group which may be substituted by 1 - 3 independent R¹¹'s or a phenyl group having substituent R⁹ at p-position (wherein R¹¹'s and R⁹ independently represent a halogen atom, an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q85416

Application No.: 10/518,405

atom, a nitro group, a cyano group, -A-R⁴ (wherein A is -CO-, -CO₂-, -O-, -NHCO- or -NHCONH-, and R⁴ is a hydrogen atom or an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom) or -A'-(CH₂)n-R⁴ (wherein A' is -CO-, -CO₂-, -O-, -NHCO- or -NHCONH-, R⁴ is a hydrogen atom, an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a hydroxyl group, a halogen atom or an alkoxy group having 1 - 5 carbon atoms, and n is an integer of 1 or 2)}} or pharmacologically acceptable salts thereof.

- **4.** (currently amended): The tetrahydroquinoline derivative according to claim 3, where Z is a phenyl group having substituent R⁹ at p-position or a heteroaryl group having substituent R¹¹ {wherein R⁹-and-R¹¹ independently represents a halogen atom, -O-R⁴ or -NHCO-R⁴ (wherein R⁴ represents a hydrogen atom or an alkyl group having 1 5 carbon atoms which may be substituted by a fluorine atom)} or pharmacologically acceptable salts thereof.
- 5. (currently amended): The tetrahydroquinoline derivative according to claim 3, where Z is a phenyl group having substituent R⁹ at p-position or a heteroaryl group having substituent R¹¹ {wherein R⁹-and-R¹¹ represents -NHCO-R⁴ (wherein R⁴ represents a hydrogen atom or an alkyl group having 1 5 carbon atoms which may be substituted by a fluorine atom)} or pharmacologically acceptable salts thereof.
- **6. (currently amended):** The tetrahydroquinoline derivative or pharmacologically acceptable salts thereof according to any one of claims 1 and 3 to 5 and a pharmaceutically acceptable carrier or excipient.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q85416

Application No.: 10/518,405

7. - 10. (canceled).

11. (previously presented): A method of treating muscle wasting or osteoporosis,

which comprises administering to a mammal in need of such treatment, the tetrahydroquinoline

derivative or pharmacologically acceptable salts thereof according to any one of claims 1 and 3

to 5 in an amount effective to treat said diseases.

12. (previously presented): A method of treating male hypogonadism, , which

comprises administering to a mammal in need of such treatment, the tetrahydroquinoline

derivative or pharmacologically acceptable salts thereof according to any one of claims 1 and 3

to 5 in an amount effective to treat said disease.

13. (canceled).

6